Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBITDA (2016 - 2025)

Historic EBITDA for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $54.9 million.

  • Ligand Pharmaceuticals' EBITDA rose 164772.51% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 20731.92%. This contributed to the annual value of -$22.6 million for FY2024, which is 28929.83% down from last year.
  • Ligand Pharmaceuticals' EBITDA amounted to $54.9 million in Q3 2025, which was up 164772.51% from $8.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year EBITDA high stood at $54.9 million for Q3 2025, and its period low was -$36.2 million during Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' EBITDA averaged around $6.5 million, with its median value being $3.1 million (2024).
  • Data for Ligand Pharmaceuticals' EBITDA shows a peak YoY increase of 164772.51% (in 2025) and a maximum YoY decrease of 131204.82% (in 2025) over the last 5 years.
  • Over the past 5 years, Ligand Pharmaceuticals' EBITDA (Quarter) stood at $37.7 million in 2021, then crashed by 153.33% to -$20.1 million in 2022, then soared by 83.29% to -$3.4 million in 2023, then plummeted by 186.99% to -$9.6 million in 2024, then soared by 670.0% to $54.9 million in 2025.
  • Its last three reported values are $54.9 million in Q3 2025, $8.4 million for Q2 2025, and -$36.2 million during Q1 2025.